FDA Accepts United Therapeutics' Application to Expand Nebulized Tyvaso Use for Idiopathic Pulmonary Fibrosis

United Therapeutics Corporation's supplemental New Drug Application for nebulized Tyvaso Inhalation Solution has been accepted by the U.S. FDA. This application seeks to broaden the drug's approved indications to include treating idiopathic pulmonary fibrosis (IPF). The FDA's review is expected to conclude in late April 2027, potentially offering a new therapeutic option for patients with this serious lung condition.